Reuters: Health News | 24NewsPage

McDonald's to offer first-ever organic burger, in Germany

A McDonald’s logo is seen at one of the chain’s restaurants in San Francisco, California, May 6, 2015. Reuters/Robert Galbraith <span class="articleLocation”>McDonald’s Corp will offer its first-ever 100 percent organic beef hamburger for a limited time in Germany, as a growing number of global diners demand food that is more natural and less processed. The move from the world’s biggest…

Over long term, diet and exercise are best to prevent diabetes

A person receives a test for diabetes during Care Harbor LA free medical clinic in Los Angeles, California September 11, 2014. Reuters/Mario Anzuoni (This story has been refiled to correct the affiliation of researcher in paragraph 3) By Kathryn Doyle <span class="articleLocation”>(Reuters Health) – In a head-to-head comparison over 15 years, diet and exercise outperformed the drug metformin in preventing…

‘TraumaMan’ helps doctors save humans, spares animals

<span class="articleLocation”>(Reuters Health) – Doctors who need to operate on injured patients in emergencies have long practiced their lifesaving procedures on live animals, but now a replica of a human, called TraumaMan, is helping to modernize their training. Thanks to a partnership between the manufacturer of TraumaMan – Seattle-based Simulab – and the animal rights organization People for the Ethical…

Kenya Airways resumes West Africa flights banned due to Ebola

Kenya Airways has resumed flights to Liberia and Sierra Leone after Kenyan health officials lifted a ban placed last year due to the Ebola virus. The carrier, one of the biggest in Africa, stopped flying to Monrovia and Freetown in August last year, losing routes worth tens of millions of dollars in annual revenue. It recorded huge losses in its…

Amgen's leukemia drug gets conditional European approval

An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. Reuters/Robert Galbraith <span class="articleLocation”>European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments. The U.S. Food and Drug Administration in December approved Blincyto for acute lymphoblastic leukemia (ALL), which…

AbbVie's arthritis drug succeeds in two mid-stage studies

<span class="articleLocation”>AbbVie Inc said its experimental drug improved symptoms of rheumatoid arthritis in patients in two mid-stage studies, putting the treatment on track for late-stage studies by the end of the year. Following the success of the trials, AbbVie said it would not buy the rights to Belgium-based Galapagos NV’s arthritis drug filgotinim, as planned. Galapagos shares were down 20…

Roche skin cancer combination therapy gets EU panel backing

The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014. Reuters/Aly Song Roche is expecting the European Commission this year to issue a final decision on a drug combination to treat advanced skin cancer, based on a drug panel’s positive opinion made public on Friday. The European Union’s…

Novartis' new heart drug on track for approval in Europe

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. Reuters/Vivek Prakash Novartis AG’s new heart failure drug Entresto is on track to be approved for use in Europe by the end of the year after it received the backing of EU regulators, the company said on Friday. Entresto, also known as LCZ696, is the first…

Simulation suits teach medical students empathy

Medical student Ludwika Wodyk fumbles her way slowly down the stairs, her movements encumbered by heavy strapping around her limbs and body, her vision distorted by special goggles. She is one of a group of medical students in Poland being given the chance to experience first-hand how it can feel to be an ageing patient. The students at the University…

Novo Nordisk successfully completes diabetes drug phase 3a trial

Danish pharmaceutical company Novo Nordisk has successfully completed the second phase 3a trial with its diabetes drug semaglutide, it said on Friday. “We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycaemic control and greater weight loss than 2.0 mg exenatideonce-weekly,” chief science officer Mads Krogsgaard Thomsen said in a statement….

1 2 4